Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2011-08-16
2011-08-16
Rawlings, Stephen (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C514S002600, C514S008100, C530S300000, C530S350000, C530S345000, C424S278100, C424S280100, C424S277100
Reexamination Certificate
active
07998486
ABSTRACT:
The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
REFERENCES:
patent: 5869035 (1999-02-01), Link et al.
patent: 5879675 (1999-03-01), Galili
patent: 6187306 (2001-02-01), Pardoll et al.
patent: 6218166 (2001-04-01), Ravindranath et al.
patent: 6333028 (2001-12-01), Berd
patent: 6361775 (2002-03-01), Galili
patent: 6713055 (2004-03-01), Schiff
patent: 6943239 (2005-09-01), Holgersson et al.
patent: 7005126 (2006-02-01), Link et al.
patent: 2004/0191229 (2004-09-01), Link et al.
patent: 2005/0201993 (2005-09-01), Link et al.
patent: 2007/0014774 (2007-01-01), Link et al.
patent: 2007/0014775 (2007-01-01), Link et al.
Abdel-Motal et al. (J. Virol. Jul. 2006; 80 (14): 6943-6951).
Naicker et al. (Org. Biomol. Chem. Mar. 7, 2004; 2 (5): 660-664).
Galili et al. (Cancer Immunol. Immunother. 2004; 53: 935-945).
Meldal et al. (Current Op. Chem. Biol. 1997; 552-563).
Brocke et al. (Biorg. Med. Chem. 2002; 10: 3085-3112).
LaTemple et al. (Cancer Res. 1999; 59: 3417-3423).
Manches et al. (Haematologica. May 2005; 90 (5): 625-634).
Macher et al. (Biochim. Biophys. Acta. 2008; 1780 (2): 75-88).
ATCC Cell Lines and Hybridomas, Eighth Edition, 1994, edited by Robert Hey, PhD, et al., published by American Type Culture Collection, Rockville, Maryland USA (1994), 4 pages.
Chamberlain, et al. (2000) Expert Opinion on Pharmacology, 1(4):603-614.
Galili et al. (2001) “Preparation of Autlogous Leukemia and Lymphoma Vaccines Expressing Alpha-Gal Epitopes,” J. Hematotherpay and Stem Cell Research, 10(4):501-511.
LaTemple, et al. (1996) “Synthesis of alpha-Galactosyl Epitopes by Recombinant α1,3Galactosyltransferase for Opinization of Human Tumor Cell Vaccines by Anti-Galactose,” Cancer Research, 56:3069-3074.
LaTemple et al. (1999) “Increased Immunogenicity of tumor vaccines complexed with anti-gal: studies in knockout mice for α1, 3galactosyltransferase,” Cancer Research, 59(4):3417-3423.
Gorelik, et al. (1995) “Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α1,3Galactosyltransferase gene transfection,” Cancer Research, 55(18):4166-4173.
Galili et al. (2003) “Expression of α-gal epitopes on ovarian carcinoma membranes to be used as novel autologous tumor vaccine,” Gynecologic Oncology, 90(1):100-108.
Yoshimura, et al. (2001) “Expression of xenoantigen transformed human cancer cells to be susceptible to antibiody-mediated cell killing,” Cancer Letters, 164(2):155-160.
Larson, et al. (1989) “Isolation of cDNA encoding a murine UDPgalactose:β-D-galactosyl-1,4-N-acetyl-D-glucosaminide α-1,3-galactosyltransferase: Expression cloning by gene transfer,” Proc. Natl. Acad. Sci. USA, 86:8227-8231.
Tratschin, et al. (1985) “Adeno-Associated Virus Vector for High-Frequency Integration, Expression, and Rescue Genes in Mammalian Cells,” Molecular and Cellular Biology 5(11):3251-3260.
Chapter 4. Reverse Transcriptase and the Generation of Retroviral DNA. Retroviruses, Edited by John M. Coffin, Seteph H. Hughes and Harold E. Varmus, 1997, Cold Spring Harbor Laboratory Press, pp. 121-125.
Miller and Rosman (19989) “Improved retroviral vectors for gene transfer and expression,” Biotechniques 7(9):984-6.
Genbank Entry for M28247.1 at the National Center for Biotechnology Information, Submitted Sep. 22, 1989.
Genbank Entru for X05157.1 at the National Center for Biotechnology Information, J. Gen Virol. 68 (PT 3), 683-693, (1987).
van Elsas et al. (2001) “Elucidating the Autoimmune and Antitumor Effector Mechanism of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with B16 Melanoma Vaccine: Comparison of Prophylaxis and Therapy,” J. Exp. Med. 194(4):481-489.
Galili, U., et al., Intratumoral Injection of a-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines, J. Immunol., 178(7):4676-4687 (Apr. 2007).
Galili, U., The a-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy, Immunology and Cell Biology, 83:674-686 (2005).
Rossi, et al., Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes, Cancer Res., 65(22):10555-10561 (Nov. 2005).
Jaipuri Firoz
Link Charles J.
Mautino Mario R.
Rossi Gabriela
Vahanian Nicholas N.
Cooley LLP
NewLink Genetics Corporation
Rawlings Stephen
LandOfFree
Enhanced immunogenicity of tumor associated antigens by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhanced immunogenicity of tumor associated antigens by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced immunogenicity of tumor associated antigens by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2682445